If you or a loved one has taken Tysabri and are concerned about the risk of PML, understanding the evidence behind risk factors is essential. Decades of pharmacovigilance have established that certain patient characteristics—such as JC virus antibody status, duration of therapy, and prior immunosuppressant use—elevate the likelihood of developing this rare brain infection. This page summarizes the current scientific understanding of who may be most at risk and what monitoring strategies are recommended.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations, including the statute of limitations, is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed in the prescribing information to alert healthcare professionals and patients to the serious nature of this adverse event. PML is caused by the reactivation of the JC virus, which typically remains dormant in healthy individuals. In patients receiving Tysabri, the drug's mechanism of action—blocking the adhesion molecule alpha-4 integrin—prevents immune cells from entering the central nervous system, thereby allowing the virus to replicate unchecked. The clinical presentation of PML can be subtle initially, with symptoms such as progressive weakness, cognitive decline, visual disturbances, and speech difficulties. Diagnosis often requires brain MRI and cerebrospinal fluid analysis for JC virus DNA. The condition usually leads to severe disability or death, as noted in the boxed warning. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, as the prescribing information advises that physicians weigh the expected benefit against the risk of PML. The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events, its severity makes it a primary safety concern. The boxed warning emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication.
For patients in Ohio who have been harmed by Tysabri-associated PML, legal action may be an option. The statute of limitations for personal injury claims in Ohio is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because PML can have a delayed onset, and symptoms may not appear until months or years after starting Tysabri. The "discovery rule" in Ohio allows the statute to begin when the patient knew or reasonably should have known that the injury was caused by the drug. Given that PML is a rare and serious condition, patients may not immediately connect their symptoms to Tysabri, especially if they have been on the drug for an extended period. Adequacy of warnings is a key issue in product liability cases. The FDA boxed warning clearly states the risk of PML and the need for monitoring. However, plaintiffs may argue that the warnings were insufficient or that healthcare providers did not adequately communicate the risk to patients. The TOUCH Prescribing Program, a restricted distribution program for Tysabri, is designed to ensure that patients are informed about PML risks and that monitoring occurs. Nonetheless, failures in this program or in physician-patient communication could form the basis of a claim. The timeline between Tysabri exposure and documented harm is another important factor. PML typically occurs after prolonged treatment, often beyond two years, as noted in the prescribing information. This latency period can complicate the statute of limitations calculation, as the injury may not be apparent until years after the drug was first administered. Patients and their attorneys must carefully document the date of first Tysabri infusion, the onset of PML symptoms, and the date of diagnosis to determine whether the claim falls within Ohio's two-year window. In summary, Tysabri-associated PML is a severe adverse event with well-defined risk factors and a clear FDA warning. For Ohio patients, the statute of limitations for filing a claim is generally two years from discovery of the injury. Given the complexity of PML diagnosis and the potential for delayed onset, affected individuals should seek legal counsel promptly to preserve their rights. The medical evidence underscores the importance of monitoring and early intervention, while legal considerations hinge on the adequacy of warnings and the timing of harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or should have been discovered. This is known as the discovery rule, which allows the clock to start when the patient knew or reasonably should have known that the injury was caused by the drug.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.